Virgil Dalm, MD, PhD
Internist-clinical immunologist
Erasmus MC, Rotterdam, the Netherlands

Biography

Virgil Dalm (1978) obtained a PhD-degree in 2003, based on his thesis entitled: Somatostatin receptors and their ligands in the human immune system. It was during this research project that his interest in clinical immunology grew and after obtaining his medical degree in 2005, he specialized in Internal Medicine and Clinical Immunology (2011). Since 2011 he is a staff member of the department of internal medicine, division of clinical immunology and the department of immunology of the Erasmus MC, Rotterdam, the Netherlands. He is responsible for clinical care for adult patients with primary and secondary immunodeficiency disorders. Research focusses on determining non-infectious complications in primary immunodeficiencies, including skin, endocrine and psychiatric disorders, showing that also non-immunological features are part of primary immunodeficiencies. Moreover, primary immunodeficiencies as part of syndromic disorders including Jacobsen syndrome and Netherton syndrome have been identified and current area of interest includes identifying novel genetic defects leading to primary immunodeficiencies, which might be candidates for gene-targeted therapy in patients. Several new genetic defects have been identified and are under current evaluation. This has resulted in clinical introduction of novel therapeutic options.

5 key references:

Meesilpavikkai K, Dik WA, Schrijver B, Nagtzaam NMA, Posthumus-van Sluijs SJ, van Hagen PM, Dalm VASH. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). *J Allergy Clin Immunol*. 2018

Wentink MWJ, Mueller YM, Dalm VASH, Driessen GJ, van Hagen PM, van Montfrans JM, van der Burg M, Katsikis PD. Exhaustion of the $CD8^+$ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta. *Front Immunol*. 2018

Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M, Joshi AD, de Buck S, Doucet J, Guerini D, Kalis C, Pylvaenaeinen I, Soldermann N, Kashyap A, Uzel G, Lenardo MJ, Patel DD, Lucas CL, Burkhart C. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib. *Blood*. 2017

Meesilpavikkai K, Dik WA, Schrijver B, Nagtzaam NM, van Rijswijk A, Driessen GJ, van der Spek PJ, van Hagen PM, Dalm VA. Novel Heterozygous Mutation in the *STAT1* SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation. *Front Immunol*. 2017

Dalm VA, Driessen GJ, Barendregt BH, van Hagen PM, van der Burg M. The 11q Terminal Deletion Disorder Jacobsen Syndrome is a Syndromic Primary Immunodeficiency. *J Clin Immunol*. 2015